期刊
JOURNAL OF BIOMEDICAL SCIENCE
卷 19, 期 -, 页码 -出版社
BIOMED CENTRAL LTD
DOI: 10.1186/1423-0127-19-47
关键词
Mesenchymal stem cell; Portal vein; Insulin-producing cells; Transplant
资金
- Taipei Veterans General Hospital [V99E1-004, V99C1-201]
- Program for Progress Towards Top-Level University in National Yang Ming University
- National Science Council Grant [NSC 98-2314-B-075-015-MY3, NSC 97-2320-B-010-019-MY3]
- Medical Research Grant [TSGH-C101-121, NDMC-D101-3-3]
Background: Although diabetes mellitus (DM) can be treated with islet transplantation, a scarcity of donors limits the utility of this technique. This study investigated whether human mesenchymal stem cells (MSCs) from umbilical cord could be induced efficiently to differentiate into insulin-producing cells. Secondly, we evaluated the effect of portal vein transplantation of these differentiated cells in the treatment of streptozotocin-induced diabetes in rats. Methods: MSCs from human umbilical cord were induced in three stages to differentiate into insulin-producing cells and evaluated by immunocytochemistry, reverse transcriptase, and real-time PCR, and ELISA. Differentiated cells were transplanted into the liver of diabetic rats using a Port-A catheter via the portal vein. Blood glucose levels were monitored weekly. Results: Human nuclei and C-peptide were detected in the rat liver by immunohistochemistry. Pancreatic beta-cell development-related genes were expressed in the differentiated cells. C-peptide release was increased after glucose challenge in vitro. Furthermore, after transplantation of differentiated cells into the diabetic rats, blood sugar level decreased. Insulin-producing cells containing human C-peptide and human nuclei were located in the liver. Conclusion: Thus, a Port-A catheter can be used to transplant differentiated insulin-producing cells from human MSCs into the portal vein to alleviate hyperglycemia among diabetic rats.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据